By Heide Oberhauser-Aslan

FRANKFURT--German healthcare company Fresenius SE & Co. KGaA (FRE.XE) has a good chance of acquiring Pfizer Inc.'s (PFE) medical devices arm in a deal that could be announced soon, according to two people familiar with the matter.

These people say that Fresenius could pay some $1.5 billion for the business, which Pfizer acquired last year when it bought Hospira, Inc. for around $16 billion. Hospira manufactures injectable drugs and infusion technologies and biotech-drug knockoffs called biosimilars. When Pfizer bought Hospira last year, it was clear that Pfizer was mainly interested in the smaller competitor's biosimilars business and would probably put the medical-devices arm up for sale.

The medical-device business, which includes infusion pumps, would boost Fresenius' presence in the U.S., where its Fresenius Kabi unit, which also sells infusion technology, doesn't yet have a strong presence.

A Fresenius spokesman declined to comment on the matter. Pfizer wasn't immediately available to comment.

Write to Heide Oberhauser-Aslan at Heide.Oberhauser@wsj.com

(END) Dow Jones Newswires

June 24, 2016 12:16 ET (16:16 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Pfizer Charts.